Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

This study is comparing two approaches after surgery for liver cancer (hepatocellular carcinoma, HCC): adding radiotherapy with an immunotherapy drug (sintilimab) versus standard TACE (a procedure that blocks blood supply to the tumor site) in patients at high risk for the cancer coming back. **You may be eligible if...** - You are aged 18–80 and have had liver cancer removed surgically (R0 resection) - Your surgical margin was less than 1 cm and you have at least one high-risk recurrence factor (e.g., microscopic blood vessel invasion, AFP over 400, or tumor larger than 5 cm) - Your surgery was within the past 4 months - Your liver and blood count levels meet the required thresholds **You may NOT be eligible if...** - Your imaging showed remaining cancer in the liver or major blood vessel invasion before surgery - You have previously received targeted therapy, immunotherapy, or other systemic anti-cancer treatment for this liver cancer - You have severe heart function abnormalities Talk to your doctor to see if this trial is right for you.